Increase in quinolones prescriptions for children (0–10 years old) in Brazil
Introduction: Quinolones are frequently associated with adverse effects such as tendinopathies and joint damage. However, the safety of quinolone use in pediatric patients remains inadequately established, with limited recommended applications. This study aimed to investigate the escalating consump...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2025-03-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/20177 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Quinolones are frequently associated with adverse effects such as tendinopathies and joint damage. However, the safety of quinolone use in pediatric patients remains inadequately established, with limited recommended applications. This study aimed to investigate the escalating consumption of quinolones among Brazilian children aged 0–10 years.
Methodology: An interrupted time series analysis was conducted to examine fluctuations in quinolone consumption within the pediatric population. Data were sourced from the Brazilian National Controlled Products Management System (SNGPC). Analysis of variance and joinpoint regression were employed to assess yearly variations in commercial unit sales of quinolones.
Results: Brazil witnessed the consumption of approximately 93 million commercial units of quinolones by the entire population, with 1 million units prescribed for children (0–10years). The surge in quinolone utilization among children during this period exceeded 50% (p < 0.05), a statistically significant increase compared to the 24% growth observed in the entire population. Regression analysis indicated an annual linear growth of around 9% (year on year) in Brazil for quinolone use among children.
Conclusions: Our study revealed a concerning rise in quinolone prescriptions for Brazilian children aged 0–10 years, underscoring the imperative for cautious use due to limited safety data and acknowledged risks, such as musculoskeletal damage. Healthcare providers should prioritize safer alternatives when possible, focusing on children`s well-being and combating antimicrobial resistance. Advocacy for prudent prescribing practices and increased awareness is crucial, along with further research to comprehensively understand long-term effects and establish evidence-based guidelines for quinolone use in pediatric populations.
|
|---|---|
| ISSN: | 1972-2680 |